DUBLIN – Kiadis Pharma NV filed a marketing authorization application (MAA) with the EMA for ATIR-101, an adjunctive treatment for patients with hematological malignancies undergoing haploidentical (partially matched) allogeneic hematopoietic stem cell transplantation (HSCT).